Lucid Diagnostics Inc. (LUCD)
- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $0.61
- As of
Kresmion compiles this page from LUCD's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Lucid Diagnostics Inc. (LUCD): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-22.
See the full LUCD dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for LUCD on one page. Preview it with sample data, then open it live with a free account.
Preview the LUCD dossierActive signals for LUCD
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 14.8%, EPS $-0.08 vs $-0.0697 estimate
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 86% of LUCD (2026Q2)
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 35.2% - EPS $-0.08 vs $-0.1234 estimate
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 11.0% - EPS $-0.1 vs $-0.1124 estimate
- mediumEARNINGS_MISS
Q1-2026: Missed consensus by 100.7% - EPS $-0.17 vs $-0.0847 estimate
FREE, NO ACCOUNT
Every signal on LUCD, as it fires
New filings, 13F moves and cross asset signals on LUCD land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in LUCD (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 54948X109 · 2026Q2 | $76K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 54948X109 · 2026Q2 | $39K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, LUCD
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
LUCD against its peers
LUCD's operating margin of -1054.8% ranks in the 18th percentile of 24 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | LUCD | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 4.7M USD | 42.5M USD | 18 | 24 |
| Gross margin | n/a | 57.6% | n/a | 20 |
| Operating margin | -1054.8% | -45.7% | 18 | 24 |
| Net margin | -1232.7% | -54.0% | 18 | 24 |
| Return on equity | -530.4% | -77.1% | 13 | 19 |
| 1 year | -48.6% | -29.0% | 27 | 23 |
Peers (24): APYX, ECOR, HYPR, OWLT, LNSR, SERA, EBRCZ, LUNG, ZOMDF, OM, MYO, STIM, QTRX, MDNC, POSC, MDAI, COCH, TELA, SNWV, SRTS, ELMD, XTNT, RPID, TLSI. Left out: RTGN (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (LUCD: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow LUCD on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to LUCD for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.